PapersFlow Research Brief
Multiple Sclerosis Research Studies
Research Guide
What is Multiple Sclerosis Research Studies?
Multiple Sclerosis Research Studies are scientific investigations into the neurologic impairment assessment, diagnostic criteria evolution, fatigue measurement, phenotypic classification, and disease mechanisms of multiple sclerosis, encompassing 103,697 published works.
Multiple Sclerosis Research Studies include foundational work on rating neurologic impairment using the Expanded Disability Status Scale (EDSS) as described in 'Rating neurologic impairment in multiple sclerosis' by Kurtzke (1983), which combines grades across eight Functional Systems. Diagnostic criteria have evolved through revisions like the 2010 McDonald criteria by Polman et al. (2011) simplifying lesion dissemination demonstration via imaging, and the 2017 revisions by Thompson et al. (2017). The field totals 103,697 papers with no specified 5-year growth rate.
Research Sub-Topics
McDonald Criteria Revisions
This sub-topic covers the evolution and updates to the McDonald diagnostic criteria for multiple sclerosis, including major revisions in 2001, 2005, 2010, and 2017. Researchers study improvements in sensitivity, specificity, and incorporation of MRI and CSF findings for earlier and more accurate diagnosis.
Expanded Disability Status Scale
This sub-topic focuses on the Expanded Disability Status Scale (EDSS) and its validation for rating neurologic impairment in MS patients. Researchers investigate its reliability, responsiveness to change, and modifications for better outcome measurement in trials.
Fatigue Severity Scale in MS
This sub-topic examines the Fatigue Severity Scale (FSS) and its application to assess fatigue in multiple sclerosis patients. Researchers explore its psychometric properties, correlates with brain lesions, and responsiveness to interventions.
MS Phenotypic Classification
This sub-topic addresses classification schemes for MS phenotypes such as relapsing-remitting, primary progressive, and secondary progressive forms. Researchers study genetic, imaging, and clinical predictors to refine phenotypes for personalized medicine.
Neuromyelitis Optica Spectrum Disorders
This sub-topic covers diagnostic criteria and differentiation of NMOSD from MS, focusing on aquaporin-4 antibodies and longitudinal extensive transverse myelitis. Researchers investigate overlapping features, misdiagnosis rates, and distinct treatment responses.
Why It Matters
Multiple Sclerosis Research Studies enable standardized neurologic impairment assessment via the EDSS from 'Rating neurologic impairment in multiple sclerosis' by Kurtzke (1983, 14,644 citations), facilitating consistent clinical trial outcomes across studies. Revised diagnostic criteria, such as those in 'Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria' by Polman et al. (2011, 9,697 citations) and 'Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria' by Thompson et al. (2017, 7,511 citations), allow earlier and more accurate MS diagnosis using MRI for lesion dissemination in space and time, improving patient management timelines. Recent funding of nearly $800,000 US to Dr. Fang Liu's team at CAMH advances regenerative therapies toward clinical testing, while UC Riverside researchers identified two compounds for remyelinating damaged axons with National Multiple Sclerosis Society support.
Reading Guide
Where to Start
'Rating neurologic impairment in multiple sclerosis' by Kurtzke (1983) first, as it establishes the foundational EDSS scale used across subsequent diagnostic and progression studies.
Key Papers Explained
Kurtzke (1983) 'Rating neurologic impairment in multiple sclerosis' provides the EDSS baseline for impairment grading. Poser et al. (1983) 'New diagnostic criteria for multiple sclerosis: Guidelines for research protocols' and McDonald et al. (2001) 'Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis' introduce early criteria emphasizing lesion dissemination, revised by Polman et al. (2005, 2011) and Thompson et al. (2017) to integrate advancing MRI evidence and simplify requirements.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent preprints explore proteomics for MS biology ('Longitudinal proteomic profiling of cerebrospinal fluid in untreated multiple sclerosis defines evolving disease biology'), AI reclassification ('AI-driven reclassification of multiple sclerosis progression'), myelin injury timing ('Myelin injury precedes axonal injury and symptomatic onset in multiple sclerosis'), cognitive subtypes ('Large-scale online assessment uncovers a distinct Multiple Sclerosis subtype with selective cognitive impairment'), and therapy comparisons ('Comparative effectiveness of disease-modifying therapies for highly active relapsing-remitting multiple sclerosis'). Funding supports regenerative therapies by Dr. Fang Liu ($800,000) and UC Riverside remyelination compounds.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Rating neurologic impairment in multiple sclerosis | 1983 | Neurology | 14.6K | ✕ |
| 2 | Diagnostic criteria for multiple sclerosis: 2010 Revisions to ... | 2011 | Annals of Neurology | 9.7K | ✓ |
| 3 | Diagnosis of multiple sclerosis: 2017 revisions of the McDonal... | 2017 | The Lancet Neurology | 7.5K | ✓ |
| 4 | New diagnostic criteria for multiple sclerosis: Guidelines for... | 1983 | Annals of Neurology | 7.4K | ✕ |
| 5 | Recommended diagnostic criteria for multiple sclerosis: Guidel... | 2001 | Annals of Neurology | 6.9K | ✕ |
| 6 | The Fatigue Severity Scale | 1989 | Archives of Neurology | 5.8K | ✕ |
| 7 | Diagnostic criteria for multiple sclerosis: 2005 revisions to ... | 2005 | Annals of Neurology | 5.0K | ✓ |
| 8 | International consensus diagnostic criteria for neuromyelitis ... | 2015 | Neurology | 4.3K | ✓ |
| 9 | New Multiple Sclerosis Phenotypic Classification | 2014 | European Neurology | 4.2K | ✕ |
| 10 | Multiple sclerosis | 2008 | The Lancet | 4.2K | ✕ |
In the News
Researchers gain funds to advance regenerative therapy ...
An international research team has secured nearly $800,000 (about CA$1.1 million) to advance a potential regenerative therapy for multiple sclerosis (MS) toward clinical testing.
New Funding Fuels Development of First Potentially Regenerative Treatment for Multiple Sclerosis
**Toronto, ON (September 15, 2025)**–– A Canadian-led international research team, spearheaded by Dr. Fang Liu at the Centre for Addiction and Mental Health (CAMH) has received nearly $800,000 US (...
Researchers receive new funding to advance promising ...
A Canadian-led international research team, spearheaded by Dr. Fang Liu at the Centre for Addiction and Mental Health (CAMH) has received nearly $800,000 US ($1,137,868 CAD) in new funding to advan...
New hope for MS | UCR News | UC Riverside
from the National Multiple Sclerosis Society. They have identified two compounds that could remyelinate damaged axons.
Alberto Ascherio receives Breakthrough Prize for ...
2025 Breakthrough Prize Recognizes Trailblazers in Multiple Sclerosis Research (The Scientist) ## About The Author Amy Roeder Senior Editor, Harvard Chan Magazine; Senior Writer in the Office of Co...
Code & Tools
`msprog` is an R package providing tools for exhaustive and reproducible analysis of disability progression in multiple sclerosis (MS) from longitu...
# Diagnosing-Multiple-Sclerosis-Using-Machine-Learning The purpose of this repository is to showcase various Machine Learning algorithms to diagn...
### Abstract:
This is the code for the paper R. Kaur, R. Motl, R. Sowers, and M. E. Hernandez "A Vision-Based Framework for Predicting Multiple Sclerosis and Par...
## Repository files navigation # combiMS Data, code and analysis results of the CombiMS project.
Recent Preprints
Longitudinal proteomic profiling of cerebrospinal fluid in untreated multiple sclerosis defines evolving disease biology
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system, but the molecular mechanisms underlying its course remain incompletely understood. We measured 4789 cerebros...
AI-driven reclassification of multiple sclerosis progression
Multiple sclerosis (MS) affects 2.9 million people. Traditional classification of MS into distinct subtypes poorly reflects its pathobiology and has limited value for prognosticating disease evolut...
Myelin injury precedes axonal injury and symptomatic onset in multiple sclerosis
The timing of the biological onset of multiple sclerosis (MS) is unclear. We used high-throughput discovery proteomics and samples from presymptomatic patients with MS and matched healthy controls ...
Large-scale online assessment uncovers a distinct Multiple Sclerosis subtype with selective cognitive impairment
Cognitive impairments in Multiple Sclerosis (MS) are prevalent and disabling yet often unaddressed. Here, we optimised automated online assessment technology for people with MS and used it to chara...
Comparative effectiveness of disease-modifying therapies for highly active relapsing-remitting multiple sclerosis despite previous treatment – a systematic review and network meta-analysis
Comparative assessments of all available disease-modifying therapies (DMTs) in patients with highly active relapsing-remitting multiple sclerosis (RRMS) are lacking, even though some of these DMTs ...
Latest Developments
Recent developments in Multiple Sclerosis research include promising early results for a new BTK inhibitor, fenebrutinib, which has shown to reduce relapse rates in relapsing MS and delay disability progression in primary progressive MS, with trial results expected in early 2026 (MS Australia, Nature). Additionally, AI-driven analysis suggests MS may follow two distinct biological subtypes with different nerve damage patterns, indicating a more complex disease classification (Multiple Sclerosis News Today, Nature Medicine).
Sources
Frequently Asked Questions
What is the Expanded Disability Status Scale in MS research?
The Expanded Disability Status Scale (EDSS) evaluates neurologic impairment in MS by grading eight Functional Systems from 0 (normal) to 5 or 6 (maximal impairment) and assigning an overall score from 0 (normal) to 10 (death due to MS). Kurtzke (1983) introduced this in 'Rating neurologic impairment in multiple sclerosis'. It remains a standard for tracking disability progression.
How have McDonald criteria for MS diagnosis evolved?
The McDonald criteria were revised in 2001 by McDonald et al., integrating MRI for dissemination in time and space, then updated in 2005 by Polman et al., 2010 by Polman et al., and 2017 by Thompson et al. to simplify imaging requirements and incorporate new evidence. These revisions enable earlier diagnosis without requiring multiple clinical attacks in some cases.
What tool measures fatigue in MS studies?
The Fatigue Severity Scale by Krupp (1989) quantifies fatigue in MS and other conditions through validated tests of internal consistency. It compares fatigue levels, such as in MS versus systemic lupus erythematosus. This scale supports research into fatigue as a disabling symptom.
What are the main MS phenotypes?
Lublin (2014) in 'New Multiple Sclerosis Phenotypic Classification' re-examined 1996 categories of relapsing-remitting, primary progressive, secondary progressive, and progressive relapsing MS. The updated scheme reflects increased pathologic understanding. It aids in prognosticating disease course.
How is MS distinguished from neuromyelitis optica?
Wingerchuk et al. (2015) in 'International consensus diagnostic criteria for neuromyelitis optica spectrum disorders' define NMO as distinct from MS, linked to AQP4-IgG antibodies, with criteria covering optic nerve, spinal cord, and broader CNS involvement. Prior criteria required optic and spinal involvement but now include expanded presentations.
Open Research Questions
- ? What molecular mechanisms define evolving MS disease biology, as probed by longitudinal cerebrospinal fluid proteomics in untreated patients?
- ? How can AI-driven data analysis reclassify MS progression subtypes to better predict treatment response and disease evolution?
- ? Does myelin injury precede axonal damage and symptomatic MS onset, and by how many years?
- ? What characterizes the MS subtype with selective cognitive impairment identified through large-scale online assessments?
- ? Which disease-modifying therapies show superior effectiveness in highly active relapsing-remitting MS via network meta-analysis?
Recent Trends
Preprints from the last six months highlight proteomics tracking 4789 cerebrospinal fluid proteins in 1040 samples from 438 MS individuals, AI reclassification of progression for 2.9 million affected people, myelin injury evidence ~7 years presymptomatically, cognitive impairment in 4526 UK MS Register participants, and network meta-analyses of disease-modifying therapies for highly active RRMS. Funding news includes nearly $800,000 US ($1,137,868 CAD) to Dr.
Fang Liu at CAMH for regenerative therapy and National Multiple Sclerosis Society support for UC Riverside's two remyelination compounds.
Research Multiple Sclerosis Research Studies with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Multiple Sclerosis Research Studies with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.